ArticleTranslational cancer research2025
Incidence, clinical features, and survival outcomes of primary malignant conjunctival tumor: a US population-based retrospective cohort analysis based on the SEER database (1975-2018).
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-Resolution Anterior Segment Optical Coherence Tomography Characteristics of Conjunctival Tumors.Journal of clinical practice and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary malignant conjunctival tumors (PMCT) are rare. Their clinicopathological characteristics and survival outcomes are not well understood. The Surveillance, Epidemiology, and End Results (SEER) database includes approximately 30% of the total US. In this study, we aimed to investigate the epidemiology, clinical characteristics, and prognosis of PMCT via SEER. Methods: Data on microscopically confirmed PMCT patients from 1975 to 2018 were retrieved. Patients who were lost to active follow-up, those for whom PMCT was not the primary malignant tumor, and those with unknown death information, laterality, race, or those who survived for less than 1 month after diagnosis were excluded. Disease-specific survival (DSS) and overall survival (OS) were the primary endpoints, calculated through the Kaplan-Meier analysis and log-rank tests. Univariate and multivariate Cox regression analyses were conducted to recognize independent predictive factors for DSS and OS. Results: In total, we identified 2,853 eligible patients diagnosed with PMCT, with an average age of 61.25 years, among which 1,678 (58.82%) were males, 2,464 (86.37%) were whites, 1,567 (54.92%) were married, and 2,125 (74.48%) were in localized SEER stage. The three major types were lymphoma (39.64%), squamous cell carcinoma (SCC) (34.88%), and melanoma (21.98%). The overall incidence of PMCT was 0.136/100,000 between 1975 and 2020, with an annual incidence rate of 0.929 [95% confidence interval (CI): 0.289-1.573, P<0.05]. Multivariate Cox regression analysis discovered age, sex, marital status, histological type, SEER stage, and surgery as independent prognostic variables. Age ≥75 years [≥75 Conclusions: PMCT incidence increased after 1975 and decreased after 1997. Age, histological type, SEER stage, and surgery were all significantly associated with DSS and OS. Age ≥75 years, melanoma, and distant SEER stage were associated with worse DSS, while age ≥75 years, male, unmarried status, distant SEER stage were related to worse OS and lymphoma was related to better OS. Surgery may improve the prognosis of patient with PMCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.